Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLIN: Brolucizumab vs Aflibercept in nAMD with Persistent Fluid
NCT03710564Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Best-Corrected Visual Acuity at 52 weeks. Started Oct 2018; status: terminated.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03710564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710564.